ADC Therapeutics S.A. cash flow to debt ratio of -32.16% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ADC Therapeutics S.A.'s free cash flow has decreased 13.42% from $-124.70M last year to $-141.44M, signaling decreasing performance

ADC Therapeutics S.A.'s debt to equity ratio is -0.54, signaling that the company spent its equity and risk bankruptcy.

ADC Therapeutics S.A.'s debt to equity ratio is -0.54, signaling that the company spent its equity and risk bankruptcy.

ADC Therapeutics S.A. has negative EBITDA, making leverage ratio unreliable

ADC Therapeutics S.A.'s interest coverage ratio is -2.28, which means that the company struggles to meet interest obligations, signaling financial risk.

ADC Therapeutics S.A.'s profit margin has increased (-22.35%) in the last year from -222.83% to -173.02%, signaling increasing performance

ADC Therapeutics S.A.'s short-term assets of $306.33M exceed its short-term liabilities of $70.16M

ADC Therapeutics S.A.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ADC Therapeutics S.A.'s return on equity of 65.27%, is higher than 15.00%, indicating good performance

ADC Therapeutics S.A.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ADC Therapeutics S.A. had positive net income in only 0 out of 5 years, indicating unstable earnings

ADC Therapeutics S.A. has negative free cash flow, indicating the company is burning cash rather than generating it

ADC Therapeutics S.A. has negative free cash flow, indicating cash burn

ADC Therapeutics S.A.'s yearly earnings has increased -9.64% since last year from $-157.85M to $-142.62M, signaling increasing performance

ADC Therapeutics S.A.'s yearly revenue has increased 3.83% since last year from $70.84M to $73.55M, signaling increasing performance

ROIC -51.57% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ADC Therapeutics S.A.'s 3-year revenue CAGR of -27.09% is negative, indicating declining revenue over the past 3 years

ADC Therapeutics S.A. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

ADC Therapeutics S.A. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ADC Therapeutics S.A. has insufficient data to evaluate this check.

ADC Therapeutics S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ADC Therapeutics S.A. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ADC Therapeutics S.A. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ADC Therapeutics S.A. has insufficient data to evaluate this check.

ADC Therapeutics S.A. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ADC Therapeutics S.A. has negative shareholder equity; price-to-book is not meaningful and the check fails

ADC Therapeutics S.A. has a price-to-sales ratio of 2.20x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue